ArticleIDCases2026
Progressive neurological decline in a measles survivor: A case report of subacute sclerosing panencephalitis in Zambia.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of subacute sclerosing panencephalitis in a 14-year-old boy who presented to specialized care 17 months after the onset of symptoms, at advanced disease stage with cognitive decline, seizures, myoclonus and dystonia. A history of infantile measles, combined with characteristic electroencephalography, neuroimaging, and elevated cerebrospinal fluid measles IgG levels, confirmed the diagnosis. The prolonged delay to presentation, driven by barriers to healthcare access, limited community and provider awareness of subacute sclerosing panencephalitis, and social stigma resulted in presentation at stage 3 disease and precluded any meaningful therapeutic interventions. Additionally, empirical antituberculosis therapy was initiated despite negative cerebrospinal and stool GeneXpert MTB/RIF results, illustrating the diagnostic anchoring that occurs in tuberculosis endemic settings. This case highlights the critical importance of early recognition of subacute sclerosing panencephalitis, the need to strengthen healthcare access and neurological diagnostic capacity in resource limited settings and the risk of empiric treatment practices that may delay appropriate diagnosis and management. With the global resurgence of measles, increased awareness and surveillance for subacute sclerosing panencephalitis in high-burden settings are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.